TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

$117 Million

Revance Therapeutics

Follow-on Offering

Lead Left Bookrunner, November 2015

Revance Therapeutics
Revance Therapeutics is a clinical-stage biotechnology company focused on the development of neuromodulators for aesthetic and therapeutic conditions. Revance’s lead compound is DaxibotulinumtoxinA for Injection (RT002), which is an injectable neurotoxin that integrates the Company’s purified botulinum toxin type A molecule with its proprietary peptide technology. RT002 is being pursued as a treatment for glabellar, forehead and lateral canthal lines (crow’s feet) in addition to multiple therapeutic conditions including cervical dystonia, plantar fasciitis, upper limb spasticity and chronic migraines.